Optimizing a Unique Cancer Vaccine for Intradermal Delivery

September 15, 2017
Muctarr Sesay
Muctarr Sesay

Muctarr Sesay, PhD, is chief scientific officer and vice-president of Bioconjugation at Goodwin Biotechnology.

,
Mark Tomai

,
Steven Fuller

Steven Fuller, PhD, is chief operating officer at Panacea Pharmaceuticals.

,
John Price

John Price is the global marketing communications manager at 3M.

,
Dave Cunningham

Dave Cunningham is director, corporate development at Goodwin Biotechnology.

BioPharm International, BioPharm International-09-15-2017, Volume 2017 eBook, Issue 2
Page Number: 31-35

Using a hollow microstructured transdermal system to deliver vaccine directly to the dermis.

3M Drug Delivery Systems and Panacea Pharmaceuticals are collaborating to deliver Panacea’s investigational cancer vaccine, PAN- 301-1, directly to the dermis via the 3M hollow microstructured transdermal system (hMTS).

PAN-301-1 vaccine is a biologic that cannot be administered orally, or via a transdermal patch; therefore, it was thought that intradermal delivery to the skin could potentially be the optimal route of administration. The hMTS offers high-volume, reproducible, direct delivery capability to the highly-vascularized dermis.

Download the

.

 

Article Details

BioPharm International eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 31-35

Citation

When referring to this article, please cite it as S. Fuller et al., "Optimizing a Unique Cancer Vaccine for Intradermal Delivery, " BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).